Ajanta Pharma Limited · NSE:AJANTPHARM

Ajanta Pharma — Q1 FY2017 Earnings Presentation

27 slides from Ajanta Pharma's earnings presentation, Jul 26, 2016

  1. Slide 1: Investor Presentation Q1 FY 2017

    Investor Presentation Q1 FY 2017 26th July 2016 26th July 2016 www.ajantapharma.com 1 of 27

  2. Slide 2: Content

    Content Industry Update Financial Highlights India Emerging Financial Markets Highlights USA Infrastructure 26th July 2016 2 of 27

  3. Slide 3: India

    26% July 2016 3 of 27 India ajanta

  4. Slide 4: India Branded Generic Business

    India Branded Generic Business  Cardiology Specialty  Ophthalmology Segment  Dermatology  Pain Management  14 Divisions Focused  3,000+ MRs Marketing  190+ Products  About 70% products First to Market  Leadership in sub therapeutic segments Established  Strong Brand Equity Player  Consist

  5. Slide 5: India Sales – Q1

    India Sales – Q1 Branded Revenue# (Rs. cr.) 19% 157 Therapeutic Break-up (Rs. cr.) 132 32% 66 13% 7% 50 42 Q1 FY 2016 Q1 FY 2017 37 35 37 21% -68% 16 12 Total India 10 5 Revenue@ (Rs. cr.) 9% 162 Ophthalmology Dermatology Cardiology Pain Mgt. Institution 148 Q1 FY 2016 Q1 FY 2017 Q1 FY 2016 Q1 FY 20

  6. Slide 6: IPM - Ranking

    IPM - Ranking Rank Jun 2016 Jun 2015 Mar 2005 Ophthal 5 5 28 Derma 13 13 98 Cardio 20 21 38 Pain 44 46 NA Ajanta 33 33 88 26th July 2016 IPM = Indian Pharmaceutical Market Source: IMS 6 of 27

  7. Slide 7: Within Segments Ajanta Way Ahead

    Within Segments Ajanta Way Ahead Jun 2016 - MAT 29% (Source: IMS) 21% 20% 20% 17% 13% 13% 13% 10% 10% Pharma Market Dermatology Cardiology Ophthalmology Pain Mgt. IPM Ajanta Pharma 26th July 2016 IPM = Indian Pharmaceutical Market 7 of 27

  8. Slide 8: Faster than Industry - IPM

    Faster than Industry - IPM 36% 29% 26% 23% 21% 14% 13% 12% 10% 10% Mar-2013 Mar-2014 Mar-2015 Mar-2016 Jun-2016 IPM Ajanta Pharma 26th July 2016 IPM = Indian Pharmaceutical Market Source: IMS 8 of 27

  9. Slide 9: Emerging Markets

    Emerging Markets 26th July 2016 9 of 27

  10. Slide 10: Global Presence

    Global Presence USA West Asia CIS (3 Countries) (6 Countries) South East Asia (3 Countries) India Africa (19 Countries) 26th July 2016 10 of 27

  11. Slide 11: Emerging Markets – Building Brands

    Emerging Markets – Building Brands  Asia – 334 Product  Africa – 1,190 Registrations  Rich product pipeline under registration and under development in R&D  Asia - Cardio, Pain, MED, GI, Antibiotic, Therapeutic Derma, Anti Histamine Segments  Africa - Anti Malaria, Multivitamin, Cardio, Antibio

  12. Slide 12: EM Revenue Q1 FY 2017 (Consolidated)

    EM Revenue Q1 FY 2017 (Consolidated) Total Revenue (Rs. cr.) 20% 287 Revenue Break-up (Rs. cr.) 239 32% 194 147 4% 89 93 Q1 FY 2016 Q1 FY 2017 -86% 3 0 Africa Asia Others 26th July 2016 Q1 FY 2016 Q1 FY 2017 EM = Emerging Markets 12 of 27

  13. Slide 13: USA

    26th July 2016 13 of 27 USA

  14. Slide 14: USA – Enhancing Presence

    USA – Enhancing Presence Revenue (Rs. cr.) 10 243% 3 Q1 FY 2016 Q1 FY 2017 Sales & Marketing ANDA approval status (till date)  1 product launched during the Qtr  Final Approvals – 11  2 ANDA approvals received during the Qtr  Tentative approval - 1  Total 8 products commercialized till date  U

  15. Slide 15: Infrastructure

    Infrastructure 26th July 2016 15 of 27

  16. Slide 16: Manufacturing

    Manufacturing Formulation Manufacturing  3 existing facilities in Aurangabad, Maharashtra (1 USFDA & WHO Pre-Q approved)  1 Facility at Mauritius  Dahej (Gujrat) - undertaking regulatory filing batches  Guwahati (Assam) – Work commenced – Investment > Rs. 300 cr. API Manufacturing  1 Facility a

  17. Slide 17: R&D

    R&D R&D spend & % of Oper. Income (Excluding Capex)  Team increased to 750+ scientists  Q1 FY 2017 revenue spend Rs. 32 cr. (Rs. 18 cr. – Q1 FY 2016) 6% 5% 106 4% 4% 70 5% 50 37 37 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 26th July 2016 17 of 27

  18. Slide 18: Financial Highlights

    Financial Highlights 26th July 2016 18 of 27

  19. Slide 19: P&L Synopsis – Q1 FY 2017 (Consolidated)

    P&L Synopsis – Q1 FY 2017 (Consolidated) Rs. cr. Q1 FY 2017 % to Sales Q1 FY 2016 % to Sales % Growth Exports 297 62% 242 61% 23% Domestic 162 34% 148 37% 9% Other Op. Income 17 4% 6 2% 195% Total Gross Revenue 476 395 20% EBITDA 167 35% 123 31% 36% PBT 158 33% 119 30% 33% PAT 120 25% 86 22% 39% Tot

  20. Slide 20: Detailed P&L - Q1 FY 2017 (Consolidated) (Ind AS)

    Detailed P&L - Q1 FY 2017 (Consolidated) (Ind AS) Q1 Rs. cr. FY 2017 FY 2016 Income from Operations 476 395 20% Materials consumed 99 21% 103 26% Employee Benefit 70 15% 59 15% Finance Cost 1 0% 1 0% Depreciation 13 3% 10 3% Other Expenses 140 28% 111 28% Total expenses 323 68% 284 72% Operational P

  21. Slide 21: Ind AS Reconciliation (Consolidated)

    Ind AS Reconciliation (Consolidated) Rs. cr. Reserve Profit Reconciliation Particulars Reconciliation Q4 FY 2016 Q1 FY 2016 FY 2016 FY 2016 Net Profit/Reserves as per 106.31 83.84 401.41 1,154.37 Accounting Standard Fair Value Adjustment of 1.60 1.38 4.45 10.37 Financial Assets Employee Benefits – A

  22. Slide 22: Consistent Track Record (Consolidated)

    Consistent Track Record (Consolidated) Consolidated Gross Revenue PAT (Rs. cr.) & PAT Margin (%) (Rs. cr.) 11% 12% 19% 21% 23% 1,743 1,485 401 1,216 310 937 234 685 112 77 2012 2013 2014 2015 2016 2012 2013 2014 2015 2016 26th July 2016 22 of 27

  23. Slide 23: Consistent Track Record (Consolidated)

    Consistent Track Record (Consolidated) EBITDA Margin Net Margin 23% (%) 21% (%) 34% 34% 19% 31% 24% 21% 11% 12% 2012 2013 2014 2015 2016 2012 2013 2014 2015 2016 RONW ROCE (%) 50% 47% (%) 43% 45% 40% 42% 37% 32% 29% 22% 26th July 2016 2012 2013 2014 2015 2016 2012 2013 2014 2015 2016 23 of 27

  24. Slide 24: Consistent Track Record (Consolidated)

    Consistent Track Record (Consolidated) EPS Dividend per share 8 46 (Rs.) (FV Rs. 2/-) (Rs.) 6 35 27 4 3 13 2 9 2012 2013 2014 2015 2016 2012 2013 2014 2015 2016 Dividend Payout Book Value per share (%) (Rs.) 133 19% 19% 18% 15% 96 13% 67 45 34 26th July 2016 2012 2013 2014 2015 2016 2012 2013 2014 2

  25. Slide 25: Consistent Track Record (Consolidated)

    Consistent Track Record (Consolidated) Total Debt / Equity Receivable Days 0.67 (Ratio) (Nos.) 77 80 65 60 63 0.32 0.22 0.09 0.08 2012 2013 2014 2015 2016 2012 2013 2014 2015 2016 92 Payable Days Inventory Days (Nos.) (Nos.) 131 134 59 99 48 44 85 40 82 26th July 2016 2012 2013 2014 2015 2016 2012 2

  26. Slide 26: Thank You!

    For updates and company information please visit our website: www.ajantapharma.com For specific queries, contact: Rajeev Agarwal rajeev.agarwal@ajantapharma.com THANK YOU! 022-66061377 Ajanta Pharma Limited Ajanta House, Charkop, Kandivli (W), Mumbai 400 067 CIN No. - L24230MH1979PLC022059 26th July

  27. Slide 27: Disclaimer

    Disclaimer This presentation may include certain ‘forward looking statements’, based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materiall

Ajanta Pharma — Q1 FY2017 Earnings Presentation on 6ix